Gap Between Invoice And Real Prices Widening, QuintilesIMS Says
Global spending on medicine is set to reach nearly $1.5 trillion by 2021, but including price concessions and rebates drops that figure 25% to $1 trillion, according to a new forecast report from QuintilesIMS.
You may also be interested in...
Sandoz needs to do another study to satisfy FDA, while Amgen says it faces a slow pace of patent litigation with AbbVie.
Net spending on all drugs rose 8.5% to $310bn in the US in 2015 when discounts, rebates and other price concessions are considered, annual IMS review says.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.